The 18-year-old girl with cerebral venous thrombosis after the AstraZeneca vaccine admitted to the San Martino hospital in Genoa remains in conditions “stable in their severity”. Despite the two surgeries to remove the cerebral thrombus and to reduce the cranial pressure caused by the hemorrhage, he is in resuscitation with a reserved prognosis. But there is no certainty that the cause of the cerebral venous thrombosis was the serum Vaxzevria, since she had taken a hormonal drug that could be responsible for the adverse reaction.
Because after the case of the 18-year-old with thrombosis, the AstraZeneca vaccine should only be intended for over 60s
Another woman, from Lucca, 42, is in intensive care at the Cisanello hospital in Pisa after a stroke: she too had been voluntarily vaccinated with AstraZeneca on 26 May. Both women are under 60 years old and currently the Italian drug agency (Aifa) and the Ministry of Health recommend the administration of the serum to over 60s even though Ema, the European agency, has ordered the administration from 18 years upwards. . Austria and Denmark have eliminated the vaccine, the United States has never authorized it, in France and Germany the restrictions are in place.
We chose to use it because the doses remained in the refrigerators. And then the Open Days of the Regions started “on a voluntary basis”. Matteo Bassetti, who works in the hospital where the 18-year-old is hospitalized, explained yesterday that the case “must not trigger psychosis”. In an interview with AdnKronos Health, the doctor and researcher explained that “it was right to report the case quickly to the competent pharmacovigilance bodies but thrombosis can also be caused by the simultaneous administration of other drugs. Now I don’t know the case of the girl. thoroughly even if it is managed here in the hospital where I work, but there may be other drugs involved. When vaccinating against Covid, the doctor must be informed if you are taking specific therapies “.
Bassetti also recalled that “the contraceptive pill has had 200 thrombotic events per million vaccinated women and I do not think that no woman has thought of giving it up. Treatment with heparime has recorded 5 thousand thrombotic events on 1 million doses of heparin. The viral vector anti-Covid vaccine such as AstraZeneca or J&J has registered 6 cases per million vaccinated “. “Now it will be understood what triggered the thrombosis of the cavernous sinuses, they are always very serious. But a careful investigation is also needed to establish the presence of malformations, if the anti-Covid vaccine has amplified a response that would have occurred anyway and the vaccine has nothing to do with it. Pharmacovigilance will tell us if this is an event related to the AstraZeneca vaccine “.
The story of the 18-year-old girl with cerebral venous thrombosis after the AstraZeneca vaccine
The appeal: “Do not use AstraZeneca for vaccinations under 60”
Yet many do not think like him. “We are opposed to the AstraZeneca Open Days because the administration of this vaccine to subjects under 40, especially women, could involve more risks than benefits”, wrote in a letter published by the Ligurian regional councilor Ferruccio Sansa 24 volunteer vaccinators of Genoa. Among the signatures stand out that of Anna Rubartelli, who teaches Hematology at the San Raffaele in Milan, that of the endocrinologist Marcello Bagnasco of the University of Genoa and Paola Minale, former director of Allergology of the San Martino. And yesterday he said his also Alessandro Bonsignore, president of the Genoa Medical Association: “Without a single scientific voice, vaccination with AstraZeneca has become a political choice that risks creating panic”.
As the Aifa report explained last week, we talk about those rare cases characterized by thrombosis of the cerebral venous sinuses (TSVC) and / or thrombosis of the splanchnic veins, often associated with the presence of thrombus in multiple sites and thrombocytopenia, with severe hemorrhages and sometimes signs of disseminated intravascular coagulation (DIC). These events were almost exclusively observed within approximately three weeks of vaccination in healthy subjects less than 60 years of age, predominantly women. And with a very low frequency: for the Vaxzevria vaccine, a total of 169 cases of cerebral venous sinus thrombosis and 53 cases of splanchnic vein thrombosis, often associated with thrombocytopenia, have been reported, out of a total of 34 million doses administered between the EU and UK.
For events of venous thrombosis in atypical sites associated with thrombocytopenia, a rate of approximately one case per 100,000 vaccinated has been estimated. The cases reported in the UK pharmacovigilance systems in the latest report published on 20 May are also in line with this figure (309 cases for 23.9 million first doses with Vaxzevria vaccine). In Italy as of April 26, 34 cases of venous thrombosis in atypical sites have been reported, 18 of which associated with thrombocytopenia4. Compared to the administrations carried out with Vaxzevria, therefore, 0.45 cases per 100,000 vaccinated are observed, since it could be affected by the lesser representativeness of the Italian sample compared to the European and Anglo-Saxon data.
“Cause of thrombosis found with AstraZeneca and J&J vaccines”
The AstraZeneca problem and the second dose
Il Fatto Quotidiano recalls that the letter of the 24 vaccinating doctors was sent to the Ligurian opposition groups while in the office of the extraordinary commissioner, General Francesco Paolo Figliuolo, they explain that the decisions are up to Aifa and the Ministry of Health, where for the the moment does not change anything on the Open Days. Meanwhile, in Genoa the deputy prosecutor Francesco Pinto and the prosecutor Stefano Puppo have opened a file, at the moment without hypothesis of crime, on the case of the eighteen year old. She had taken her first dose on May 25th. On June 3 she went to the emergency room of San Martino: she said she had a headache, the CT scan was negative and they sent her home. On June 5 she returned with a hemiparesis. In Lucca there is an exhibit of the 42-year-old’s family members.
Even the immunologist Antonella Viola in May called for a reasoned stop for AstraZeneca, hoping that it would be administered only to men or to all over 60s, removing women under 60 from inoculation, even voluntary. understandable rush to vaccinate as much as possible and following the example of Great Britain, the regions continue to dispose of the doses of AstraZeneca with “voluntary” vaccination. But the risk is that cases of cerebral venous sinus thrombosis increase and news stories end up frightening people and creating fear of other vaccines as well.
Research still in the preprint phase and signed by some German scientists claims to have found the cause of blood clots and thromboembolic complications that have emerged in some rare cases in vaccinations with Vaxzevria (ChAdOx1 nCov-19, AstraZeneca) or with COVID- 19 Vaccine Janssen of Johnson & Johnson. And he says the problem is potentially solvable. Precisely for this reason it would be right to choose the path of prudence, since in the meantime the doses of the other serums increase in availability. A stop at AstraZeneca for the categories at risk would benefit a vaccination campaign that must be carried out in maximum safety. Health Minister Roberto Speranza should move. Before the mess of the permit then became a ban with the ballet between Aifa and Ema some time ago is reproduced. With worse damage than last March.